Fcm Iv Injection 500Mg/10Ml (1 Box = 1 Injection)

Caution is advised to be exercised to avoid paravenous leakage when administering Ferric Carboxymaltose. Paravenous leakage of Ferric Carboxymaltose at the injection site may lead to irritation of the skin and potentially long lasting brown discoloration at the site of injection. In case of paravenous leakage, the administration of Ferric Carboxymaltose must be stopped as soon as possible.
Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes. The risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.
In patients with liver dysfunction, parenteral iron is advised to only be administered after careful benefit/risk assessment. Parenteral iron administration is advised to be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.